Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis

Area of Science:

• Neuroimmunology
• Endocrinology
• Autoimmune Diseases

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a T helper 1 (Th1)-mediated autoimmune demyelinating disease, serving as a model for multiple sclerosis (MS).
• Both EAE and MS exhibit amelioration during late pregnancy, hinting at hormonal influences on immune responses.

Purpose of the Study:

• To investigate the therapeutic potential of estriol in treating experimental autoimmune encephalomyelitis (EAE).
• To explore estriol's efficacy in other cell-mediated autoimmune diseases.
• To understand the immunological mechanisms underlying estriol's effects in EAE.

Main Methods:

• Estriol, progesterone, or placebo pellets were administered to mice during the effector phase of adoptive EAE.
• Disease severity was assessed using clinical scores.
• Autoantigen-specific humoral and cellular immune responses were analyzed.

Main Results:

• Estriol treatment significantly reduced EAE severity compared to placebo; progesterone had no effect.
• Estriol administration led to increased levels of anti-myelin basic protein (MBP) IgG1 antibodies.
• MBP-specific T-lymphocyte responses in estriol-treated mice showed elevated interleukin-10 (IL-10) production, primarily from T lymphocytes.

Conclusions:

• Estriol, a hormone associated with pregnancy-related immune modulation, demonstrates therapeutic potential for EAE.
• These findings suggest estriol could be a novel treatment for multiple sclerosis and other Th1-mediated autoimmune diseases.
• The study highlights the role of IL-10 in estriol-mediated immune suppression in EAE.